$PSNL

Hall Christopher M sold $1.5M of PSNL

Hall Christopher M (Chief Executive Officer) sold 100,000 shares of Personalis, Inc. (PSNL) at $15.08 ($1.51M total) on 2026-07-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hall Christopher M
Published Jul 10, 2026, 12:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 10, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PSNL
Neutral
medium confidence
Mentioned
$PSNL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

The CEO’s open-market sale at a specified price is new information, but it is not accompanied by any new operational or financial catalyst in the text.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 structure suggests limited incremental fundamental impact.

03

What to watch

The filing does not state tax, diversification, or personal liquidity needs; without those details, the signal should be treated as low-conviction.

Relevance 5/10Novelty 3/10Timing: latest Form 4 filed for the 2026-07-09 insider sale

Background

This is an SEC Form 4 insider transaction disclosure for Personalis, Inc. (PSNL).

Company-level read

Ticker impact

$PSNLNeutralMedium confidence
Context

PSNL CEO Christopher M. Hall sold 100,000 shares in an open-market transaction at $15.0800/share under a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size and price, but it does not include new company fundamentals, guidance, or regulatory/financial events.

Market effects

No clear sector read-through from a single CEO 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • Personalis, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • Christopher M. Hall

    CEO and director who sold 100,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$PSNLMed

Personalis (PSNL) Has Investors Asking A Fresh Question

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

$TEMHighAI 9/10

Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.